Table 1.
Pharmacokinetic features of docetaxel
| Authors | Patients | N | Dose range (mg/m2) | Cmax (μg/mL) | AUC (μg h/mL) | CL (L/h/m2) | Ethnicity |
|---|---|---|---|---|---|---|---|
| Extra et al.3 | Solid tumor (Phase 1) | 65 | 5–115 | 2.41† | 5.93† | NA | |
| Burris et al.4 | Solid tumor (Phase 1) | 58 | 5–115 | 5.9 ± 1.9† | 18.3 ± 5.4† | NA | |
| Taguchi et al.2 | Solid tumor (Phase 1) | 27 | 10–90 | 1.61 ± 0.59‡ | 2.44 ± 0.83‡ | Japanese | |
| Yamamoto et al.5 | NSCLC | 29 | 60 | 1.30―3.82 | 2.66 ± 0.91 | 24.5 ± 6.4 | Japanese |
| Rosing et al.6 | Solid tumor | 24 | 100 | 2.6 ± 0.5 | 3.1 ± 0.9 | 34.8 ± 9.3 | NA |
| ten Tije et al.7 | Solid tumor (<65 years) | 20 | 75 | 4.06 ± 1.38 | 5.69 ± 2.27 | 15.4 ± 6.94 | White/Black |
| Solid tumor (≥65 years) | 20 | 75 | 3.54 ± 1.58 | 6.01 ± 3.23 | 16.6 ± 10.0 | ||
| Minami et al.8 | Solid tumor | 69 | 60 | 1.588 | 2.68 | 29.4 L/h | Japanese |
†
Pharmacokinetic parameters obtained at 100 mg/m2 dose.
‡
Pharmacokinetic parameters obtained at 60 mg/m2 dose. AUC, area under the curve; CL, total body clearance; Cmax, maximum plasma concentration; NA, not available; NSCLC, non-small cell lung cancer.